CLE18 Antibody

Shipped with Ice Packs
In Stock

Description

CLEC18A Antibody (C-type Lectin Domain Family 18 Member A)

CLEC18A is an immune-modulatory protein expressed in myeloid cells and the liver. It enhances antiviral responses by acting as a TLR3 co-receptor and is implicated in hepatitis C-associated cryoglobulinemia .

Key Antibody Characteristics (Proteintech 21013-1-AP) :

PropertyDetails
TargetCLEC18A (recognizes CLEC18A/B/C isoforms)
ApplicationsWB (1:500–1:1000), IHC (1:20–1:200), ELISA
ReactivityHuman, mouse, rat
Molecular Weight47–50 kDa (predicted: 50 kDa)
Host/IsotypeRabbit IgG
ImmunogenCLEC18A fusion protein
Clinical RelevanceLinked to immune activation in viral infections (e.g., H5N1, HCV) .

Research Findings:

  • CLEC18A antibodies localize to human kidney and stomach tissues, with optimal IHC staining using TE buffer pH 9.0 .

  • Functional studies highlight its role in modulating TLR3 signaling, enhancing interferon responses during viral challenges .

CLDNAntibody (Claudin 18.2)

CLDN18.2 is a tight junction protein overexpressed in gastric, pancreatic, and esophageal cancers, making it a therapeutic target.

Key Antibody Candidates and Clinical Progress:

Antibody NameTypeMechanismClinical Stage
Givastomig/ABL111CLDN18.2×4-1BB bispecificActivates 4-1BB+ T cells in tumorsPreclinical/Phase I
ZolbetuximabChimeric IgG1ADCC/CDC against CLDN18.2+ cellsPhase III (approved in Japan)
AB011Humanized mAbCombines with chemotherapy/PD-L1 inhibitorsPhase I (NCT04400383)
CLDN18.2-307-ADCAntibody-drug conjugateDelivers MMAE toxin to CLDN18.2+ tumorsPhase I

Research Findings:

  • Givastomig/ABL111 activates 4-1BB signaling only in CLDN18.2+ tumors, avoiding systemic toxicity .

    • Induces CD8+/Treg ratio increase and durable antitumor memory in mouse models .

    • No hepatotoxicity observed in primate studies .

  • Zolbetuximab improves survival in CLDN18.2+ gastric cancer (SPOTLIGHT/GLOW trials: HR 0.75 for PFS) .

  • CLDN18.2-307-ADC achieves complete tumor regression in pancreatic PDX models via lysosomal toxin delivery .

Comparative Expression and Therapeutic Relevance

TargetNormal Tissue ExpressionTumor Expression (Frequency)Therapeutic Rationale
CLEC18AMyeloid cells, liverNot explicitly linked to oncologyImmune modulation in viral infection
CLDN18.2Gastric mucosa (restricted)Gastric (58%), GEJ (60%), pancreatic (20%) Tumor-selective targeting

Ongoing Clinical Trials for CLDN18.2-Targeted Antibodies

Trial IdentifierCompoundTarget CombinationPhaseIndication
NCT04260191AMG-910CLDN18.2×CD3 bispecificIGastric/GEJ adenocarcinoma
NCT04856150Q-1802CLDN18.2×PD-L1IAdvanced solid tumors
NCT03816163Zolbetuximab + chemoN/AIIMetastatic pancreatic cancer

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
CLE18 antibody; At1g66145 antibody; F15E12CLAVATA3/ESR antibody; CLE)-related protein 18 [Cleaved into: CLE18p] antibody
Target Names
CLE18
Uniprot No.

Target Background

Function
CLE18 Antibody targets a root growth factor that regulates the pattern of root growth and lateral root development. This factor modulates the length and number of cortical cells in the root apical meristem (RAM) and influences the anticlinal asymmetric cell divisions in lateral root initiation cells. CLE18 is also an extracellular signal peptide that regulates cell fate and represses root apical meristem maintenance. Furthermore, CLE18 regulates the transition of protophloem cells from proliferation to differentiation, thus impacting the postembryonic growth capacity of the root meristem. This signaling pathway relies on CRN and CLV2.
Database Links

KEGG: ath:AT1G66145

STRING: 3702.AT1G66145.1

UniGene: At.66111

Protein Families
CLV3/ESR signal peptide family
Subcellular Location
[CLE18p]: Secreted, extracellular space.; [CLE18 C-terminus]: Secreted.
Tissue Specificity
Expressed in roots, leaves, siliques and seedlings.

Q&A

Experimental Design for CLE18 Antibody Use

Q: How should I design an experiment using the CLE18 antibody in flow cytometry, considering the need for multiple color analysis? A: For experiments involving multiple colors, such as using the CLE18 antibody, it's crucial to select fluorochromes that are compatible with your flow cytometer. Ensure that you have appropriate controls, such as single-color compensation tubes for each antibody used. If using highly expressed antigens like CD45, consider using less efficient fluorochromes like Pacific Orange. Isotype controls are essential when measuring activation markers to ensure specificity .

Data Analysis and Contradiction Resolution

Q: What strategies can I use to resolve contradictory data when using the CLE18 antibody in different experimental setups? A: Contradictory data may arise from variations in antibody lots, experimental conditions, or sample preparation. To resolve this, ensure consistency in reagent sources and experimental conditions. Use FMO (Fluorescence Minus One) tubes to validate staining patterns and consider running isotype controls to assess non-specific binding. Additionally, verify antibody specificity by using different clones or sources if available .

Antibody Validation and Specificity

Q: How can I validate the specificity of the CLE18 antibody for my research application? A: Validate the specificity of the CLE18 antibody by using Western blot or immunofluorescence on known positive controls. For flow cytometry, use FMO controls to ensure that the signal is specific to the antigen of interest. If possible, compare results with different antibody clones or sources to confirm consistency .

Optimization of Staining Protocols

Q: What are the best practices for optimizing staining protocols when using the CLE18 antibody in immunofluorescence or flow cytometry? A: For optimal staining, ensure proper fixation and permeabilization of cells. Use blocking agents to reduce non-specific binding, and optimize antibody concentrations through titration experiments. In flow cytometry, use appropriate compensation controls to adjust for spectral overlap between fluorochromes .

Advanced Research Applications

Q: How can I integrate the CLE18 antibody into advanced research applications, such as studying cellular differentiation or signaling pathways? A: To study cellular differentiation or signaling pathways, combine the CLE18 antibody with other markers specific to your pathway of interest. Use techniques like co-staining with other antibodies or integrating with biochemical assays to elucidate the role of CLE18 in these processes. Consider using live cell imaging or single-cell analysis for more detailed insights .

Troubleshooting Common Issues

Q: What are common issues encountered when using the CLE18 antibody, and how can they be addressed? A: Common issues include non-specific binding, low signal intensity, or inconsistent results. Address these by optimizing antibody concentrations, using appropriate blocking agents, ensuring proper sample preparation, and verifying antibody specificity through controls like isotype or FMO tubes .

Cross-Reactivity and Species Specificity

Q: How can I determine if the CLE18 antibody is suitable for my species of interest, and what are the implications of cross-reactivity? A: Determine species specificity by consulting the manufacturer's data or performing cross-reactivity tests. Cross-reactivity can complicate data interpretation, so ensure that the antibody is validated for your species. If cross-reactivity is a concern, consider using species-specific antibodies or alternative detection methods .

Integration with Other Techniques

Q: How can I integrate the use of the CLE18 antibody with other research techniques, such as Western blot or immunoprecipitation? A: Integrate the CLE18 antibody with techniques like Western blot by using it for immunoprecipitation followed by Western blot analysis. For immunoprecipitation, ensure that the antibody is conjugated to a suitable resin or bead. This can help in studying protein interactions or expression levels in more detail .

Advanced Flow Cytometry Techniques

Q: What advanced flow cytometry techniques can be used with the CLE18 antibody to enhance data resolution? A: Techniques like high-dimensional flow cytometry (using 9 or more colors) can be employed to analyze complex cell populations. Use instruments like the LSRII or FACSAria for such experiments. Ensure proper compensation and use FMO controls to validate staining patterns .

Future Directions in CLE18 Research

Q: What are potential future directions for research involving the CLE18 antibody, particularly in understanding its role in cellular processes? A: Future research could focus on elucidating the role of CLE18 in developmental biology, particularly in plant systems, by studying its expression patterns and interactions with other signaling molecules. Techniques like live cell imaging and single-cell RNA sequencing could provide deeper insights into its function .

Example Data Table for Experimental Design

ExperimentAntibody UsedFluorochromeControl Used
Flow CytometryCLE18 AntibodyFITCIsotype Control
ImmunofluorescenceCLE18 AntibodyDyLight 488FMO Control

Detailed Research Findings

  • Western Blot Analysis: The CLE18 antibody can be used to detect specific bands corresponding to the protein of interest, ensuring specificity and sensitivity in Western blot assays .

  • Flow Cytometry: Use of the CLE18 antibody in flow cytometry allows for the identification and characterization of cell populations expressing CLE18, enabling detailed analysis of cellular heterogeneity .

  • Immunofluorescence: This technique provides spatial information on CLE18 expression within cells, useful for studying cellular localization and interactions .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.